tweetindex
TH

AstraZenecaUS

@AstraZenecaUS · Wilmington, DE · joined 07 Jan 2009

We're transforming the future of healthcare by unlocking the power of what science can do. Intended for US HCPs. For info visit https://t.co/1B0LbPwpeO

80 608Followers
1 769Following
8 941Posts total
10.1KViews on collected posts

โพสต์ล่าสุด

Today, we announced positive high-level results from our latest Phase III CROSSING trial in people living with eosinophilic esophagitis (EoE), a chronic epithelial-driven inflammatory disease of the esophagus. Read more about the results: https://t.co/N8bIR9J7Qu https://t.co/UKLh
0:28
1.1K views · 6 likes · 1 reposts · 0 replies Open on X →
We rang the opening bell in a historic moment today at the @NYSE.  With #AZN trading on the #NYSE, we’re deepening our roots in the US and expanding our access to capital – fueling continued investment in the science behind a healthier America. https://t.co/QMHtrxMVD3
3.4K views · 10 likes · 1 reposts · 0 replies Open on X →
By deepening the collaboration between the UK and the US, we are accelerating scientific discovery and engaging with governments to deliver the next generation of medicines for patients worldwide. https://t.co/MjwWa3yZje
541 views · 2 likes · 0 reposts · 0 replies Open on X →
The visit was a fantastic opportunity to showcase the boundary-pushing science taking place at The DISC, our role in the Cambridge and UK life sciences ecosystem and our deep commitment to the United States. https://t.co/YPBbYDpUU0
1.2K views · 2 likes · 0 reposts · 1 replies Open on X →
Last week, we welcomed the US Ambassador to the UK, Warren Stephens, to The Discovery Center, our global headquarters and state-of-the-art R&D facility in Cambridge. https://t.co/lWd3F7hlxr
1.5K views · 2 likes · 0 reposts · 1 replies Open on X →
Today, the FDA has approved a new treatment option for individuals living with hypereosinophilic syndrome (HES), a rare disease driven by elevated eosinophils in the blood, which can lead to progressive organ damage over time. Read more about the approval: https://t.co/yGWxyYURFK
0:11
1.5K views · 3 likes · 0 reposts · 0 replies Open on X →
The FDA just announced the approval of a new way to self-administer therapy for people living with systemic lupus erythematosus (SLE). Learn more: https://t.co/1Ra9EW94yG https://t.co/wfjPziPC35
0:10
823 views · 4 likes · 1 reposts · 1 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

1 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 10K–100K ผู้ติดตาม ต่ำกว่าบัญชีรุ่นเดียวกันทั้งการเข้าถึงและการมีส่วนร่วม.

ยอดดูมัธยฐาน1 060บัญชีนี้956ค่ามัธยฐานของ 10K–100K
การเข้าถึง, %1.32%บัญชีนี้3.52%ค่ามัธยฐานของ 10K–100K
การมีส่วนร่วม, %0.66%บัญชีนี้1.57%ค่ามัธยฐานของ 10K–100K
ตัวชี้วัดบัญชีนี้ค่ามัธยฐานของ 10K–100Kอัตราส่วน
ยอดดูมัธยฐานต่อโพสต์1 0609561.11×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)1.32%3.52%0.37×
อัตราการมีส่วนร่วม0.66%1.57%0.42×

บัญชีอื่นในช่วงนี้ →   เปรียบเทียบกับบัญชีอื่น →   ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

82327 Apr
1.5K14 May
1.5K4 Jun
1.2K
541
3.4K5 Jun
1.1K27 Aug

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.73%27 Apr
0.20%14 May
0.20%4 Jun
0.24%
0.37%
0.32%5 Jun
0.66%27 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.57%.

What the audience does

Likes80.6%29 in total
Reposts8.3%3 in total
Replies8.3%3 in total
Bookmarks2.8%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

บัญชีที่คล้ายกัน